Water-soluble I-type photosensitizer as well as preparation method and application thereof
By modifying type I photosensitizers with PEG, a water-soluble type I photosensitizer, PEG-MTPABZ-PyC, was prepared, solving the problem of poor water solubility and realizing highly efficient photodynamic therapy in hypoxic environments, with good biocompatibility and therapeutic effect.
Patent Information
- Application Number
- CN202411015339.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-26
AI Technical Summary
Existing type I photosensitizers have poor water solubility, resulting in poor therapeutic effects of photodynamic therapy in hypoxic environments, and their hydrophobicity limits their practical application in the biomedical field.
A water-soluble type I photosensitizer, PEG-MTPABZ-PyC, was prepared by modifying a hydrophobic AIE-active photosensitizer with biocompatible macromolecular polyethylene glycol (PEG). 4,7-dibromo-2,1,3-benzothiadiazole, β-[4-[bis(4-methoxyphenyl)amino]phenyl]boronic acid, Pd catalyst, and alkaline solution were mixed and reacted through a series of chemical reactions. Subsequently, 4-methylpyridine and 11-bromoundecanoic acid were added, and finally, the mixture was reacted with PEG and the catalyst under specific conditions to obtain the water-soluble type I photosensitizer.
The prepared PEG-MTPABZ-PyC exhibits excellent water solubility and bright near-infrared fluorescence. It can effectively generate ROS such as O2·- and ·OH under hypoxic conditions, has good photostability and biocompatibility, can rapidly enter cells and kill cancer cells after white light irradiation, showing significant photodynamic therapy.
Smart Images

Figure CN118949029A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of material preparation, and specifically relates to a water-soluble I-type photosensitizer and a preparation method and application thereof. Background Art
[0002] Photodynamic therapy (PDT) continues to receive increasing research attention due to its significant advantages such as minimally invasive, high selectivity, and low resistance to drug. Photosensitizers are one of the important components of photodynamic therapy. According to the energy transfer process from triplet state to oxygen, they can be divided into type II, which is mainly based on energy transfer, and type I, which is mainly based on electron transfer. Due to typical tumor hypoxia caused by abnormal proliferation, apoptosis and tumor vascular malformations of tumor cells, the efficiency of reactive oxygen species (ROS) produced by photosensitizers (PSs) in tumors is reduced, which seriously affects the therapeutic effect of PDT. Therefore, it is necessary to develop a drug that can achieve good therapeutic effects on hypoxic tumors under normoxic and hypoxic conditions.
[0003] Photosensitizers (PSs) are generally divided into two categories, namely type I, which produces superoxide radicals (O2·-) and hydroxyl radicals (·OH) through a process dominated by electron transfer from triplet state to oxygen, and type II, which produces singlet oxygen (1O2) through a process dominated by energy transfer. This difference in the ROS production mechanism brings the advantage of low oxygen dependence to type I PSs. Therefore, type I PSs such as O2·- and ·OH generators are considered to be a promising candidate for the treatment of hypoxic tumors. However, type I PSs exhibit obvious fluorescence self-absorption and photobleaching effects, which are not conducive to long-term fluorescence imaging of cells and tumors. Although more and more AIE-active type I PSs have been developed in recent years, their hydrophobicity (derived from their molecular structure composed of many aromatic rings) has caused great obstacles to their practical application in the biomedical field. The currently reported type I photosensitizers have the problems of poor water solubility and short emission wavelength, which have limited their clinical application. Therefore, the pursuit of biocompatible, stable, and water-soluble type I PSs with aggregation-induced near-infrared fluorescence properties has great potential for clinical biomedical applications, and the development of water-soluble near-infrared type I photosensitizers is imminent. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a water-soluble type I photosensitizer and a preparation method and application thereof, so as to solve the technical problems of poor water solubility and poor PDT efficiency in anoxic environment.
[0005] To achieve the above object, the technical solution adopted by the present invention is: to provide a method for preparing a water-soluble type I photosensitizer, comprising the following steps:
[0006] S1. Mix 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid and Pd catalyst in an organic solvent, then add alkali solution, and react at 80-100° C. for 10-14 hours to obtain MTPABZCHO intermediate; the ratio of 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid, Pd catalyst and alkali solution is 30-50 mmol: 30-50 mmol: 1-3 mmol: 100-150 mL;
[0007] S2, dissolving 4-methylpyridine and 11-bromodecaneic acid in an organic solvent at a molar ratio of 4-6:5-7, stirring at room temperature for 10-14 hours, filtering, and obtaining a PyC intermediate;
[0008] S3, dissolving the MTPABZCHO intermediate and the PyC intermediate in an organic solvent, then adding alkali solution, and reacting at room temperature for 10-14 hours to obtain the MTPABZ-PyC intermediate; the ratio of the MTPABZCHO intermediate, the PyC intermediate and the alkali solution is 1-3mmol:1-3mmol:100-150μL;
[0009] S4. Dissolve the MTPABZ-PyC intermediate, PEG and catalyst in an organic solvent at a molar ratio of 3-5:1-3:6-8, react at 50-70°C for 22-26h to obtain a water-soluble type I photosensitizer (PEG-MTPABZ-PyC).
[0010] On the basis of the above technical solution, the present invention can also be improved as follows:
[0011] Furthermore, the ratio of 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid, Pd catalyst and alkali solution is 20 mmol:20 mmol:1 mmol:60 mL.
[0012] Furthermore, the reaction temperature in S1 is 90° C. and the reaction time is 12 h.
[0013] Furthermore, the organic solvent is tetrahydrofuran, toluene or methanol.
[0014] Furthermore, the Pd catalyst is Pd(PPh3)4.
[0015] Further, the alkali solution is a K2CO3 solution or a piperidine solution.
[0016] Further, the concentration of the alkali solution is 1.5-2.5 mol / L.
[0017] Furthermore, the catalyst in S4 is a mixture of carbodiimide and 4-dimethylaminopyridine in a molar ratio of 15-25:1-3.
[0018] The invention also discloses a water-soluble type I photosensitizer prepared by the preparation method.
[0019] The invention also discloses the use of the water-soluble I-type photosensitizer in the preparation of drugs for treating tumors.
[0020] The beneficial effects of the present invention are as follows: the present invention uses biocompatible macromolecular polyethylene glycol (PEG) to modify the hydrophobic AIE active photosensitizer (MTPABZ-PyC) to obtain a water-soluble type I photosensitizer (PEG-MTPABZ-PyC) with bright near-infrared fluorescence, large Stokes shift and better photostability. PEG-MTPABZ-PyC exhibits excellent water solubility (37 μg / mL) in aqueous solution. In addition, PEG-MTPABZ-PyC can effectively generate type I ROS of O2·- and ·OH and type II ROS of 1O2. In vitro cell fluorescence imaging results show that the PEG-TPABZ-PyC probe can be rapidly engulfed by cells and show bright red fluorescence, and can also effectively generate ROS such as 1O2, O2·- and ·OH after white light irradiation. The results of cytotoxicity evaluation show that PEG-TPABZ-PyC has good biocompatibility with cells in the absence of white light irradiation, but most cancer cells are killed after white light irradiation of appropriate power. Even under hypoxic conditions, PEG-MTPABZ-PyC exhibited good PDT efficiency and had important application potential in clinical tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 It is the synthetic route of the present invention;
[0022] Figure 2 1H NMR spectra of PEG, MTPAPZ-PyC and PEG-MTPAPZ-PyC;
[0023] Figure 3 Absorption and fluorescence spectra of MTPBZ-PyC and PEG-MTPBZ-PyC in tetrahydrofuran;
[0024] Figure 4 This is the fluorescence spectrum of MTPBZ-PyC in a dimethyl sulfoxide / toluene mixed solution;
[0025] Figure 5 is the UV absorption spectra of MTPATZ-PyC in different organic solvents;
[0026] Figure 6is the fluorescence spectra of MTPATZ-PyC in different organic solvents;
[0027] Figure 7 This is a physical picture of the aqueous solution of PEG MTPATZ-PyC;
[0028] Figure 8 Absorption spectra of MTPABZ-PyC and PEG MTPABZ-PyC;
[0029] Fig. 9 is the linear fitting result of the concentration and absorbance of PEG MTPBZ-PyC;
[0030] Fig.10 Comparison of water solubility of MTPBZ-PyC and PEG MTPBz-PyC;
[0031] Fig.11 The fluorescence intensity of the H2DCF-DA probe added to the MTPABZ-PyC and PEG-MTPABZPy-PyC samples changes with the illumination time;
[0032] Fig.12 The trend diagram of the UV absorption spectrum of the MTPABZ-PyC sample with ABDA probe added as a function of illumination time;
[0033] Fig.13 This is the trend diagram of the UV absorption spectrum of the sample with ABDA probe added to PEG-MTPABZ-PyC as a function of illumination time;
[0034] Fig.14 The fluorescence intensity of the samples with DHE probe added to MTPABZ-PyC and PEG-MTPABZPy-PyC changes with illumination time;
[0035] Fig.15 The fluorescence intensity of the HPF probe added to the MTPABZ-PyC and PEG-MTPABZPy-PyC samples changes with the illumination time;
[0036] Fig.16 This is the fluorescence imaging effect of PEG-MTPABZ-PyC on MKN-45 cells;
[0037] Fig.17 is the phototherapy efficacy of PEG-MTPABZ-PyC on MKN-45 cells;
[0038] Fig.18 for cell viability in hypoxic environments;
[0039] Fig.19 This is the staining image of cancer cells after adding PEG-MTPABZ-PyC. DETAILED DESCRIPTION
[0040] The specific embodiments of the present invention are described below to facilitate the understanding of the present invention by those skilled in the art. If the specific conditions are not specified in the examples, the methods are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturers are not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially. However, it should be clear that the present invention is not limited to the scope of the specific embodiments. For those skilled in the art, as long as various changes are within the spirit and scope of the present invention defined and determined by the attached claims, these changes are obvious, and all inventions and creations using the concept of the present invention are protected.
[0041] Example 1
[0042] A method for preparing a water-soluble type I photosensitizer, the synthetic route is as follows Figure 1 As shown, the following steps are included:
[0043] S1. Add 4,7-dibromo-2,1,3-benzothiadiazole (4 mmol, 1.12 g), B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid (4 mmol, 1.4 g) and Pd(PPh3)4 (0.2 mmol, 231 mg) into a two-necked flask filled with nitrogen atmosphere, then add tetrahydrofuran (20 mL) and K2CO3 solution (2 M, 12 mL), and react at 90°C for 12 h; after the reaction is completed and the mixture is cooled, dichloromethane is used to obtain the mixture. The mixture was extracted with methane (DCM) three times, and ethyl acetate / petroleum ether (1:3, v:v) was used as the eluent, and a red powder (978 mg), i.e., the MTPABZCHO intermediate, was obtained by column chromatography; the yield of the MTPABZCHO intermediate was 45%: 1HNMR (400 MHz, d-DMSO) δ=10.05 (s, 1H), 8.19-7.99 (m, 8H), 7.06-6.83 (m, 10H), 3.72 (s, 6H);
[0044] S2. 4-methylpyridine (5 mmol, 465 mg) and 11-bromodecaneic acid (6 mmol, 1.59 g) were dissolved in toluene (20 mL), and the reaction was stirred at room temperature for 12 h, filtered to obtain a white precipitate, and the precipitate was washed 3 times with ethyl acetate to obtain a PyC intermediate; the yield of the PyC intermediate was 87%: 1H NMR (400 MHz, d-DMSO) δ = 11.95 (s, 1H), 8.95 (d, 2H), 7.99 (d, 2H), 4.52 (t, 2H), 2.62 (s, 3H), 2.22 (t, 2H), 1.89 (t, 2H), 1.47 (t, 2H), 1.23 (m, 12H);
[0045] S3. Dissolve the MTPABZCHO intermediate (1 mmol, 543 mg) and the PyC intermediate (1 mmol, 357 mg) in a mixed solution of tetrahydrofuran (10 mL) and methanol (10 mL), then add piperidine (60 μL) and react at room temperature for 12 h; after the reaction, remove the solvent using a rotary evaporator, add a small amount of dichloromethane to dissolve the product, and precipitate it in low-polarity hexane for 3 times to obtain a purple powder (600 mg), i.e., the MTPABZ-PyC intermediate; the yield of the MTPABZ-PyC intermediate is 78%: 1H NMR (400 MHz, d-DMSO) δ = 1H NMR (500MHz, d-DMSO) δ = 9.02 (s, 2H), 8.16-7.91 (m, 12H), 7.13-6.88 (m, 10H), 4.52 (s, 2H), 3.76 (s, 6H), 2.04 (d, 4H), 1.44-1.23 (m, 16H);
[0046] S4, MTPABZ-PyC intermediate (0.2 mmol, 154 mg), PEG (PEG 1000 , 0.1mmol, 200mg) and carbodiimide (0.3mmol, 61mg) were dissolved in anhydrous dichloromethane (10mL) under nitrogen, and then 4-dimethylaminopyridine DMAP (0.03mmol, 4mg) dissolved in dichloromethane (2mL) was injected into the above reaction system and reacted at 60°C for 24h; after the reaction, the solution was concentrated and poured into cooled ether to precipitate a purple powder, which was repeatedly precipitated with ether to obtain a purple product, a water-soluble type I photosensitizer (PEG-MTPABZ-PyC).
[0047] Example 2
[0048] A method for preparing a water-soluble type I photosensitizer, the synthetic route is as follows Figure 1 As shown, the following steps are included:
[0049] S1. Add 4,7-dibromo-2,1,3-benzothiadiazole (3 mmol), B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid (3 mmol) and Pd(PPh3)4 (0.1 mmol) into a two-necked flask filled with nitrogen atmosphere, then add tetrahydrofuran (20 mL) and K2CO3 solution (2M, 10 mL), and react at 80°C for 14 h; after the reaction is completed, cool the mixture, extract the mixture 3 times with dichloromethane (DCM), use ethyl acetate / petroleum ether (1:3, v:v) as eluent, and obtain a red powder by column chromatography, i.e., MTPABZCHO intermediate;
[0050] S2, dissolving 4-methylpyridine (4 mmol) and 11-bromodecaneic acid (7 mmol) in toluene (20 mL), stirring the reaction at room temperature for 10 h, filtering to obtain a white precipitate, and washing the precipitate three times with ethyl acetate to obtain a PyC intermediate;
[0051] S3, dissolving the MTPABZCHO intermediate (2 mmol) and the PyC intermediate (1 mmol) in a mixed solution of tetrahydrofuran (10 mL) and methanol (10 mL), then adding piperidine (60 μL) and reacting at room temperature for 14 h; after the reaction, removing the solvent with a rotary evaporator, adding a small amount of dichloromethane to dissolve the product, and precipitating it in low-polarity hexane for 3 times to obtain a purple powder (600 mg), i.e., the MTPABZ-PyC intermediate;
[0052] S4, MTPABZ-PyC intermediate (0.25 mmol), PEG (PEG 1000 , 0.15mmol) and carbodiimide (0.3mmol) were dissolved in anhydrous dichloromethane (10mL) under nitrogen, and then 4-dimethylaminopyridine DMAP (0.03mmol) dissolved in dichloromethane (2mL) was injected into the above reaction system and reacted at 50°C for 26h; after the reaction, the solution was concentrated and poured into cooled ether to precipitate a purple powder, which was repeatedly precipitated with ether to obtain a purple product, a water-soluble type I photosensitizer (PEG-MTPABZ-PyC).
[0053] Example 3
[0054] A method for preparing a water-soluble type I photosensitizer, the synthetic route is as follows Figure 1 As shown, the following steps are included:
[0055] S1. Add 4,7-dibromo-2,1,3-benzothiadiazole (5 mmol), B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid (5 mmol) and Pd(PPh3)4 (0.3 mmol) into a two-necked flask filled with nitrogen atmosphere, then add tetrahydrofuran (20 mL) and K2CO3 solution (2M, 12 mL), and react at 100°C for 10 h; after the reaction is completed, cool the mixture, extract the mixture 3 times with dichloromethane (DCM), use ethyl acetate / petroleum ether (1:3, v:v) as eluent, and obtain a red powder (978 mg), i.e., MTPABZCHO intermediate, by column chromatography;
[0056] S2, dissolving 4-methylpyridine (6 mmol) and 11-bromodecaneic acid (5 mmol) in toluene (20 mL), stirring the reaction at room temperature for 10 h, filtering to obtain a white precipitate, and washing the precipitate three times with ethyl acetate to obtain a PyC intermediate;
[0057] S3, dissolving the MTPABZCHO intermediate (1 mmol) and the PyC intermediate (3 mmol) in a mixed solution of tetrahydrofuran (10 mL) and methanol (10 mL), then adding piperidine (60 μL) and reacting at room temperature for 10 h; after the reaction, removing the solvent with a rotary evaporator, adding a small amount of dichloromethane to dissolve the product, and precipitating it in low-polarity hexane for 3 times to obtain a purple powder (600 mg), i.e., the MTPABZ-PyC intermediate;
[0058] S4, MTPABZ-PyC intermediate (0.15 mmol), PEG (PEG 1000 , 0.05mmol) and carbodiimide (0.4mmol) were dissolved in anhydrous dichloromethane (10mL) under nitrogen, and then 4-dimethylaminopyridine DMAP (0.03mmol) dissolved in dichloromethane (2mL) was injected into the above reaction system and reacted at 70°C for 22h; after the reaction, the solution was concentrated and poured into cooled ether to precipitate a purple powder, which was repeatedly precipitated with ether to obtain a purple product, a water-soluble type I photosensitizer (PEG-MTPABZ-PyC).
[0059] Comparative Example
[0060] The difference between this comparative example and Example 1 is that step S4 is omitted, and the remaining steps are the same as those in Example 1 to obtain MTPABZ-PyC.
[0061] Taking the MTPABZ-PyC prepared in the comparative example and the PEG-MTPABZ-PyC prepared in Example 1 as examples, the following experiments were performed.
[0062] Experimental Example 1 Structural Characterization
[0063] In order to confirm the successful preparation of the water-soluble type I photosensitizer PEG-MTPABZ-PyC, the 1H NMR spectra of PEG, MTPABZ-PyC (Comparative Example) and PEG-MTPABZ-PyC (Example 1) were compared. Figure 2 As shown, commercial PEG 1000 The chemical shift of PEG-MTPABZ-PyC is 3.51ppm; MTPABZ-PyC shows some special chemical shifts, such as the chemical shift at 9.02ppm attributed to the proton hydrogen of pyridine (c position), while the chemical shifts at 3.76ppm and 4.52ppm belong to the methoxy group (b position) and the methylene group (d position), respectively; the 1H NMR spectrum of PEG-MTPABZ-PyC shows the special chemical shifts of PEG and MTPABZ-PyC at the same time, which can prove that the target product has been successfully prepared.
[0064] Absorption and fluorescence spectra were used to characterize the optical properties of MTPABZ-PyC and PEG-MTPABZ-PyC. The absorption and fluorescence spectra of MTPBZ-PyC and PEG-MTPBZ-PyC in tetrahydrofuran are shown in Figure 2. Figure 3 As shown, the MTPABZ-PyC small molecule shows three absorption peaks at 320nm, 383nm and 479nm, which are attributed to position and charge transfer transitions; after setting the excitation wavelength at 479nm, MTPABZ-PyC emits deep red fluorescence with a maximum emission wavelength of 660nm. For PEG-MTPABZ-PyC, its maximum absorption wavelength and fluorescence wavelength are the same as those of the MTPABZ-PyC small molecule, indicating that the optical properties mainly come from the MTPABZ-PyC core.
[0065] The fluorescence spectrum of MTPBZ-PyC in dimethyl sulfoxide / toluene mixed solution is shown in Figure 4 As shown, when MTPABZ-PyC is completely dissolved in dimethyl sulfoxide (DMSO) solvent, the fluorescence of MTPABZ-PyC is very weak. Low polarity toluene can be used as a poor solvent for high polarity MTPABZ-PyC, which causes MTPABZ-PyC to form aggregates in DMSO / toluene mixed solvents with high toluene content. Therefore, with the increase of toluene content, it can be observed that the fluorescence intensity of MTPABZ-PyC is significantly enhanced, indicating that MTPABZ-PyC has AIE properties, and MTPABZ-PyC has AIE properties due to the introduction of triphenylamine (TPA) electron donor.
[0066] like Figure 5 and Figure 6 As shown, the absorption spectra of MTPABZ-PyC in various organic solvents are similar, indicating that the ground state optical properties are insensitive to the polarity of the environment, while when the solvent polarity increases, the maximum fluorescence peak red-shifts, indicating that the MTPABZ-PyC molecule has an obvious ICT effect. The reason why the MTPABZ-PyC molecule has an obvious ICT effect is that the molecular structure of MTPABZ-PyC contains typical electron donor and acceptor units, so it has a typical intramolecular charge transfer (ICT) effect, which is conducive to accelerating the inter-system crossing channel to generate ROS.
[0067] Experimental Example 2 Water Solubility Test
[0068] The actual aqueous solution of PEG MTPATZ-PyC is as follows Figure 7 As shown, it can be seen that PEG MTPATZ-PyC can be evenly dissolved in water without obvious precipitation, indicating that PEG MTPATZ-PyC has good water solubility.
[0069] The absorption spectra of MTPABZ-PyC and PEG MTPABZ-PyC are shown in Figure 8 As shown, the maximum absorption wavelength of MTPABZ-PyC in DMSO / H2O mixture is 482nm, and the maximum emission wavelength peak is 660nm. For PEG-MTPABZ-PyC in aqueous solution, its maximum absorption wavelength is the same as that of MTPABZ-PyC, which indicates that the optical properties are mainly attributed to the MTPABZ-PyC core; but the fluorescence peak is red-shifted to the near-infrared fluorescence region, with a maximum emission wavelength of 670nm, which is attributed to the solvation effect.
[0070] The linear fitting between concentration and absorbance was studied to further characterize the solubility of PEG-MTPABZ-PyC in water. Fig. 9 As shown, according to the fitting formula y=0.034+0.016x, by measuring the absorbance of the saturated solution of PEG-MTPABZ-PyC, the saturated concentration of PEG-MTPABZ-PyC in water was calculated to be 37 μg / mL.
[0071] from Fig.10 The enhancement of the water solubility of PEG-MTPABZ-PyC can also be observed. MTPABZ-PyC can be dissolved in ethyl acetate organic solvent, but PEG-MTPABZ-PyC is mainly dissolved in water, while the ethyl acetate layer is clear and transparent.
[0072] Experimental Example 3: Efficiency and Types of ROS
[0073] A series of specific ROS probes were used to identify the types and efficiencies of ROS. To ensure the accuracy of the data, each MTPABZ-PyC and PEG-MTPABZ-PyC was detected three times using different ROS probes.
[0074] (1) The total ROS of MTPABZ-PyC and PEG-MTPABZ-PyC were characterized using H2DCF-DA probe. Fig.11 As shown in Figure 2, the fluorescence intensity of the H2DCF-DA probe was significantly enhanced under frequent white light irradiation, indicating that MTPABZ-PyC and PEG-MTPABZ-PyC can effectively generate ROS and Fig.11 It can be seen that the change trend of MTPABZ-PyC is higher than that of PEG-MTPABZ-PyC, that is, the efficiency of MTPABZ-PyC in generating total ROS is higher than that of PEG-MTPABZ-PyC, which is attributed to the higher effective concentration of PEG-MTPABZ-PyC.
[0075] (2) A specific ABDA probe was used to verify whether MTPABZ-PyC and PEG-MTPABZ-PyC produced type II ROS of 1O2. Fig.12 and Fig.13 As shown, the absorption intensity of ABDA decreased significantly, indicating that 1O2 was effectively produced.
[0076] (3) Type I ROS including O2·- and ·OH were further measured using DHE and HPF probes. Fig.14 As shown in the figure, the fluorescence intensity of the DHE probe was significantly increased, and the experimental group of PEG-MTPABZ-PyC showed a greater fluorescence enhancement than that of MTPABZ-PyC, indicating that both MTPABZ-PyC and PEG-MTPABZ-PyC can produce O2·- after white light irradiation, and PEG-MTPABZ-PyC is more efficient in producing O2·- than MTPABZ-PyC.
[0077] In addition, the results of the HPF probe also showed that PEG-MTPABZ-PyC was more efficient than MTPABZ-PyC in generating ·OH. Fig.15 ), which is because the concentration of effective substances in PEG-MTPABZ-PyC is lower than that in MTPABZ-PyC. Therefore, the PEGylation of PEG-MTPABZ-PyC is not only beneficial for improving hydrophilicity, but also for accelerating the generation of type I ROS.
[0078] Experimental Example 4 Fluorescence Imaging
[0079] Water-soluble photosensitizers can easily enter cells and are expected to show good fluorescence imaging and therapeutic effects. Therefore, this experimental example evaluated the cell fluorescence imaging and PDT effects of PEG-MTPABZ-PyC.
[0080] The premise of PDT efficacy is that the photosensitizer can enter cells, so we first evaluated whether the water-soluble PEG-MTPABZ-PyC can enter cells. The fluorescence imaging of PEG-MTPABZ-PyC was evaluated, and the results are as follows: Fig.16 As shown in the figure, after human gastric cancer cells (MKN-45 cells) were incubated with PEG-MTPABZ-PyC for 0.5 h, obvious red fluorescence could be observed, indicating that PEG-MTPABZ-PyC could be quickly absorbed by the cells. After prolonging the cell culture time, more cells showed bright red fluorescence, indicating that more PEG-MTPABZ-PyC had entered the cells, which was beneficial to enhance the PDT effect.
[0081] The phototherapy efficacy of PEG-MTPABZ-PyC on MKN-45 cells is shown in Fig.17As shown, the cell viability results showed that the PEG-MTPABZ-PyC aqueous solution was almost non-toxic, because most cells were still alive when the incubation concentration reached 250 μg / mL. However, when the cells absorbed different concentrations of PEG-MTPABZ-PyC and were irradiated with white light, the cancer cells could be killed well, reflecting a better PDT efficiency.
[0082] Experimental Example 5 PDT efficiency in hypoxic environment
[0083] Since free radicals ROS can effectively overcome the hypoxic effect, this experiment further evaluated the cell viability under hypoxic environment. Fig.18 As shown, when the incubation concentration of PEG-MTPABZ-PyC was higher (62.5 μg / mL, 125 μg / mL, and 250 μg / mL), cell viability was reduced after light irradiation, which strongly demonstrated that PDT was effective even under hypoxic conditions.
[0084] Live / dead cell co-staining experiments directly demonstrated the effect of PDT, with green fluorescence indicating cell survival and red fluorescence indicating cell death. Fig.19 As shown, when cells were exposed to or not exposed to light, most cells emitted green fluorescence indicating that the treated cells were alive. However, in the experimental group where cells were incubated with PEG-MTPABZ-PyC and exposed to light, obvious red fluorescence could prove that the cells were dead. Comparing the two groups, more red fluorescence appeared in the experimental group, indicating that PEG-MTPABZ-PyC had significant PDT efficiency on cancer cells.
[0085] The above experimental results show that PEG-MTPABZ-PyC exhibits good biocompatibility, can quickly enter cells, and kill cancer cells well after light irradiation; even under hypoxic conditions, PEG-MTPABZ-PyC also exhibits good PDT efficiency, proving that PEG-MTPABZ-PyC has important application potential in clinical tumor treatment.
Claims
1. A method for preparing a water-soluble type I photosensitizer, characterized in that: The following steps are involved: S1. Mix 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid and Pd catalyst in an organic solvent, then add alkali solution, and react at 80-100° C. for 10-14 hours to obtain MTPABZCHO intermediate; the ratio of 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid, Pd catalyst and alkali solution is 30-50 mmol: 30-50 mmol: 1-3 mmol: 100-150 mL; S2, dissolving 4-methylpyridine and 11-bromodecaneic acid in an organic solvent at a molar ratio of 4-6:5-7, stirring at room temperature for 10-14 hours, filtering, and obtaining a PyC intermediate; S3, dissolving the MTPABZCHO intermediate and the PyC intermediate in an organic solvent, then adding alkali solution, and reacting at room temperature for 10-14 hours to obtain the MTPABZ-PyC intermediate; the ratio of the MTPABZCHO intermediate, the PyC intermediate and the alkali solution is 1-3mmol:1-3mmol:100-150μL; S4. Dissolve the MTPABZ-PyC intermediate, PEG and catalyst in an organic solvent at a molar ratio of 3-5:1-3:6-8, react at 50-70° C. for 22-26 hours to obtain a water-soluble type I photosensitizer.
2. The method for preparing a water-soluble type I photosensitizer according to claim 1, characterized in that: The ratio of the 4,7-dibromo-2,1,3-benzothiadiazole, B-[4-[bis(4-methoxyphenyl)amino]phenyl]boric acid, Pd catalyst and alkali solution is 20 mmol:20 mmol:1 mmol:60 mL.
3. The method for preparing a water-soluble type I photosensitizer according to claim 1, characterized in that: The reaction temperature in S1 is 90° C. and the reaction time is 12 h.
4. The method for preparing a water-soluble type I photosensitizer according to claim 1, characterized in that: The organic solvent is tetrahydrofuran, toluene or methanol.
5. The method for preparing the water-soluble type I photosensitizer according to claim 1, characterized in that: The Pd catalyst is Pd(PPh3)4.
6. The method for preparing a water-soluble type I photosensitizer according to claim 1 or 2, characterized in that: The alkali solution is K2CO3 solution or piperidine solution.
7. The method for preparing the water-soluble type I photosensitizer according to claim 6, characterized in that: The concentration of the alkali solution is 1.5-2.5 mol / L.
8. The method for preparing the water-soluble type I photosensitizer according to claim 1, characterized in that: The catalyst in S4 is a mixture of carbodiimide and 4-dimethylaminopyridine in a molar ratio of 15-25:1-3.
9. A water-soluble type I photosensitizer, characterized in that: The method is prepared by any one of claims 1 to 8.
10. Use of the water-soluble type I photosensitizer according to claim 9 in the preparation of drugs for treating tumors.
Citation Information
Patent Citations
DNA (deoxyribonucleic acid) activated I-type photosensitizer for photodynamic therapy and chemotherapy combined therapy as well as synthesis method and application of DNA activated I-type photosensitizer
CN117582499A
Chemiluminescent imidazopyrazinone-based photosensitizers with available singlet and triplet excited states
WO2019211809A1
